Which medicinal products are part of the reform?
The change comprises some of the medicinal products in the group of calcium channel blockers, ACE inhibitors, angiotensin II antagonists, renin inhibitors and a single beta blocking agent.
The table below is a list of the new reimbursement status for the medicinal products concerned, listed here with the name of the active substances. The names of the medicinal products can be seen from Appendices II and III for the individual ATC groups, cf. the fact box on the right.
The reimbursement status as of 13 July 2009 for the medicinal products for cardiovascular disease in ATC groups C07, C08 and C09 for which the reimbursement will be changed.
Medicinal product group |
Active substance |
Reimbursement status |
C07: Beta blocking agents |
the combination: metoprolol and felodipine |
No general reimbursement |
C08: Dihydropyridine calcium channel blockers |
the individual substances: isradipine, nifedipine, nitrendipine, lacidipine, lercanidipine
|
Conditional reimbursement, i.e. reimbursement is granted when the general practitioner prescribes the medicinal products for: Patients with hypertension or any other type of cardiovascular disease requiring treatment, where treatment with dihydropyridine calcium channel blockers with general unconditional reimbursement
The doctor must write “tilskud” (reimbursement) on the prescription, when the patient meets the criteria. |
the combination: verapamil and trandolapril |
No general reimbursement | |
the individual substance: nimodipine |
General reimbursement | |
C09: ACE inhibitors |
the individual substances: perindopril, quinapril, benazepril, fosinopril the combinations: captopril and hydrochlorothiazide enalapril and hydrochlorothiazide (strength 20 mg + 6 mg) perindopril and indapamide perindopril and amlodipine |
No general reimbursement |
C09: Angiotensin II antagonists and renin inhibitors |
the individual substances: losartan eprosartan valsartan irbesartan candesartan telmisartan olmesartan aliskiren the combinations: losartan and hydrochlorothiazide, eprosartan and hydrochlorothiazide, valsartan and hydrochlorothiazide, irbesartan and hydrochlorothiazide, candesartan and hydrochlorothiazide, telmisartan and hydrochlorothiazide, olmesartan and hydrochlorothiazide, valsartan and amlodipine |
Conditional reimbursement, i.e. reimbursement is granted when the general practitioner prescribes the medicinal products for: Patients with hypertension or any other type of cardiovascular disease requiring treatment, where treatment with medicinal products acting on the renin-angiotensin system that are eligible for general unconditional reimbursement
The doctor must write “tilskud” (reimbursement) on the prescription, when the patient meets the criteria. |
All other cardiovascular medicinal products (‘antihypertensives’) which are not mentioned in the table will still maintain their reimbursement status.
General reimbursement means that reimbursement is automatically granted when the general practitioner prescribes the medicinal product. Most of the medicinal products in the five groups of cardiovascular medicinal products maintain general unconditional reimbursement.
Conditional reimbursement means that reimbursement is granted to the patients mentioned in the condition. The doctor can write “tilskud” (reimbursement) on the prescription, when he assesses that the patient is comprised by the condition.
No general reimbursement means that the patient must pay the full amount himself/herself.
The fact box contains a link to an alphabetical listing of all medicinal products in ATC groups C02, C03, C07, C08 and C09 with reimbursement status after 13 July – indicated as ‘no change’, ‘conditional reimbursement’ or ‘reimbursement cancelled’.